Table 2. Adverse events during combination therapy of sunitinib and ifosfamide (number of patients (%)).
|
First cycle adverse events
|
Adverse events at all combination cycles
|
|||
|---|---|---|---|---|
| All grades | Grade 3/4 | All grades | Grade 3/4 | |
| Haematological toxicity | ||||
| Anaemia | 28 | 0 | 31 | 2 |
| Thrombocytopenia | 19 | 4 | 22 | 9 |
| Neutropenia | 14 | 10 | 21 | 19 |
| Febrile neutropenia | 3 | 3 | 7 | 7 |
| Non-haematological toxicity | ||||
| Fatigue | 24 | 2 | 29 | 4 |
| Nausea | 20 | 0 | 24 | 0 |
| Constipation | 20 | 0 | 24 | 0 |
| ALAT and/or ASAT | 20 | 0 | 21 | 0 |
| Alopecia | 19 | 0 | 26 | 0 |
| Vomiting | 14 | 0 | 19 | 0 |
| Creatinine/renal | 9 | 0 | 12 | 1 |
| Hypo-/hyperkalaemia | 5/1 | 1/0 | 5/1 | 2/0 |
| Bilirubin | 5 | 0 | 6 | 0 |
| Diarrhoea | 4 | 0 | 5 | 0 |
| Pyrosis | 3 | 0 | 5 | 0 |
| TSH increase/decrease | 2/2 | 0 | 2/2 | 0 |
| Neurotoxicity | 2 | 1 | 8 | 1 |
| Anorexia | 2 | 0 | 11 | 1 |
| Haemorrhage | 1 | 1 | 1 | 1 |
Abbreviations: ALAT=alanine transaminase; ASAT=aspartate aminotransferase; TSH=thyroid-stimulating hormone.